Signs of inflammatory bowel disease (IBD) activity, shorter duration of IBD, and previous corticosteroid use and hospitalisation were associated with Clostridioides difficile infection in patients ...

The panelist discusses how recurrent Clostridioides difficile infections involve complex differential diagnosis, including persistent infection, reinfection, and other gastrointestinal conditions.

A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides ...

The study of Clostridium difficile infection (CDI) continues to reveal intricate details of its pathogenesis, epidemiology and potential novel therapies. Research has elucidated how the bacterium, ...

FMT restores gut microbiota balance by transferring stool from healthy donors, mainly for recurrent C. difficile infections. Recent data shows FMT's high efficacy in preventing recurrent C. difficile, ...

A recurrence of C. diff is common after an initial episode, with about 20% of people having a recurrence. A recurrence is ...

Antibiotic use in the outpatient setting is a significant risk factor for contracting Clostridium difficile outside of a healthcare environment, according to a study published in the journal Open ...

An infection with Clostridioides difficile (or C. diff in the trade) that occurs 72 hours after admission to the hospital is considered hospital-acquired. Medicare penalizes hospitals financially if ...

Novel C. diff vaccine shows long-term protection in animal studies, reducing illness, death, and infection recurrence, per Vanderbilt Health research.

Pre-specified secondary endpoint showed 0-11 vaccine to placebo case split for medically attended C. difficile infection (CDI), corresponding to 100% vaccine efficacy Median CDI duration was 1 versus ...

STATEN ISLAND, N.Y., Dec. 9, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule ...